N/A
N=40
AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study
Walled Off Pancreatic Necrosis
Bottom Line
View on ClinicalTrials.gov: NCT03525808 ↗Enrolled (actual)
40
Serious AEs
47.5%
Results posted
Dec 2021
Primary outcome: Primary: Number of Participants With Resolution of WON With Endoscopic Drainage — 39 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- AXIOS (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Boston Scientific Corporation
- Primary completion
- Mar 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Resolution of WON With Endoscopic Drainage |
39 | — |
| PRIMARY AXIOS Stent Related or WON Drainage Procedure Related Serious Adverse Events |
3 | — |
| SECONDARY Symptom Reduction |
29 | — |
| SECONDARY Technical Success |
40; 40 | — |
| SECONDARY Drainage Procedural Time |
22.6 | — |
| SECONDARY Resolution of WON: Radiographic Resolution Evaluated by MRI or CT |
40 | — |
| SECONDARY Time to WON Resolution |
34.1 | — |
| SECONDARY WON Recurrence |
— | — |
| SECONDARY Stent Lumen Patency |
40 | — |
| SECONDARY Fluoroscopy |
4.6 | — |
| SECONDARY Incidence of New Organ Failure |
1 | — |
| SECONDARY Change in SF-12 Score |
23.6 | — |
Summary
To demonstrate safety and effectiveness of lumen-apposing metal stents for resolution of walled off pancreatic necrosis (WONs) in patients with WONs with solid component >30%.
Eligibility Criteria
Inclusion Criteria
- Age between 22 and 75 years old
- Severe or moderately severe acute necrotizing pancreatitis, defined per the 2012 Revised Atlanta Classification.
- WON resulting from necrotizing pancreatitis per contrast-enhanced CT with the following characteristics, per the 2012 Revised Atlanta Classification:
- Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear homogeneous)
- Well defined wall
- Location-intrapancreatic and/or extrapancreatic
- Infected WON or symptomatic sterile WON Note: WON-related symptoms may include: pain, fever, leukocytosis, failure to thrive or deterioration of overall heath score, gastric outlet obstruction (GOO), weight loss, biliary obstructive symptoms, systemic inflammatory response syndrome (SIRS), deteriorating organ function, chronic nausea, lethargy, and inability to eat or gain weight
- Imaging suggestive of greater than 30% necrotic material
- WON ≥ 6cm in size
- Eligible for endoscopic intervention
- Acceptable candidate for endoscopic transluminal drainage
- Patient understands the study requirements and the treatment procedures and provides written Informed Consent
- Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post imaging study
Exclusion Criteria
- Pseudocyst
- Cystic neoplasm
- Untreated Pseudoaneurysm > 1cm within the WON
- More than one WON clearly separated and requiring drainage
- WONs that require dual modality interventions (endoscopic and percutaneous) from the beginning (i.e. deep paracolic space involvement that is inaccessible through the central drainage access)
- Prior surgical, interventional radiology or endoscopic procedures for the treatment of the WON
- Abnormal coagulation:
- INR > 1.5 and not correctable
- presence of a bleeding disorder
- platelets < 50,000/mm3
- Intervening gastric varices or unavoidable blood vessels within the access tract (visible using endoscopy or endoscopic ultrasound)
- WON that poorly approximates the GI lumen (≥1cm away)
- Pericolic gutter necrosis
- Pelvic necrosis
- Prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient
- Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study
- Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
Data sourced from ClinicalTrials.gov (NCT03525808). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.